| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $9,892,210 ) |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01AI179593 | Calcineurin Control over Aspergillus Fumigatus Antifungal Response Mechanisms | 000 | 2 | NIH | 5/23/2025 | $503,706 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R35GM142744 | The Role of the Mitochondrion in the Metabolic Stress Response to Burn Trauma | 000 | 4 | NIH | 1/15/2025 | $41,250 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HD117940 | Evaluating Maternal and Neonatal Pharmacokinetics of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - The ELECTRA Pregnancy Study | 001 | 1 | NIH | 7/2/2025 | $0 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HD117940 | Evaluating Maternal and Neonatal Pharmacokinetics of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - The ELECTRA Pregnancy Study | 000 | 1 | NIH | 6/17/2025 | $696,246 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | P20GM121293 | Center for Translational Pediatric Research | 000 | 9 | NIH | 8/6/2025 | $2,303,000 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01ES036986 | Perinatal PFAS Impact Children's Development: Examining the Roles of Placental Functional Multiomics and Protection by Maternal Exercise | 000 | 1 | NIH | 12/1/2024 | $695,853 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173107 | Next Generation Treatments for Lymphatic Malformations | 001 | 2 | NIH | 7/17/2025 | $64,035 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01AI181962 | Arkansas Center for Food Allergy Research (ArCOFAR) | 000 | 2 | NIH | 2/12/2025 | $339,490 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173107 | Next Generation Treatments for Lymphatic Malformations | 000 | 2 | NIH | 3/4/2025 | $576,324 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173537 | An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections | 000 | 2 | NIH | 3/19/2025 | $600,849 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 000 | 5 | NIH | 8/7/2025 | $1,549,910 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 000 | 5 | NIH | 8/7/2025 | $250,000 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 000 | 5 | NIH | 8/7/2025 | $161,545 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R37CA266135 | Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia | 000 | 4 | NIH | 7/30/2025 | $559,503 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL171034 | ENsuring ACcess to optimal Therapy in CF: ENACT study | 001 | 2 | NIH | 6/12/2025 | $592,346 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI180334 | PKA-Dependent Autophagy Control in Aspergillus fumigatus Pathogenesis | 000 | 2 | NIH | 5/21/2025 | $212,099 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | K23HD109727 | Salivary miRNAs as Prognostic Markers of Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia in Extremely Low Gestational Age Infants | 002 | 4 | NIH | 7/30/2025 | $159,422 |
| | 2025 | 2025 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01DK138153 | Deimplementation of Inappropriate Feeding Practices in Early Care andEducation Settings | 001 | 2 | NIH | 7/10/2025 | $613,784 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | K23HL143167 | Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients | 001 | 5 | NIH | 3/10/2025 | $17,757 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | K23HD109727 | Salivary miRNAs as Prognostic Markers of Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia in Extremely Low Gestational Age Infants | 001 | 3 | NIH | 7/24/2025 | $4,750 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | P20GM109096 | Center for Childhood Obesity Prevention | 000 | 9 | NIH | 5/30/2025 | $0 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | UG1OD024945 | Arkansas ECHO ISPCTN Site (AREIS) | 000 | 7 | NIH | 10/9/2024 | $0 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI178060 | Host-Microbe Interactions and SARS-CoV-2 Susceptibility and Symptoms in aNovel Human Challenge Model | 001 | 3 | NIH | 6/27/2025 | $95,750 |
| | 2025 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL171034 | ENsuring ACcess to optimal Therapy in CF: ENACT study | 000 | 1 | NIH | 2/14/2025 | $0 |
| | 2025 | 2023 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HD099099 | Effects of maternal obesity and inflammation on offspring brain development | 000 | 5 | NIH | 7/31/2025 | $0 |
| | 2025 | 2022 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI163301 | Calcineurin regulatory network control of Aspergillus fumigatus hyphal septation | 000 | 2 | NIH | 1/21/2025 | -$145,410 |
|
| Issue Date FY: 2024 ( Subtotal = $13,969,070 ) (Continued on the next page) |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI180334 | PKA-Dependent Autophagy Control in Aspergillus fumigatus Pathogenesis | 000 | 1 | NIH | 7/5/2024 | $225,996 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01AI181962 | Arkansas Center for Food Allergy Research (ArCOFAR) | 000 | 1 | NIH | 3/14/2024 | $339,997 |
| | 2024 | 2024 | ARKANSAS CHILDRENS RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173107 | Next Generation Treatments for Lymphatic Malformations | 001 | 1 | NIH | 6/21/2024 | $68,469 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173107 | Next Generation Treatments for Lymphatic Malformations | 000 | 1 | NIH | 3/11/2024 | $616,243 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R37CA266135 | Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia | 000 | 3 | NIH | 8/12/2024 | $489,128 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 001 | 4 | NIH | 8/28/2024 | $520,076 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 000 | 4 | NIH | 7/17/2024 | $1,827,297 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | U01DA055352 | 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium | 000 | 4 | NIH | 7/17/2024 | $412,126 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | K23HL143167 | Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients | 001 | 5 | NIH | 8/1/2024 | $150,012 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL173537 | An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections | 000 | 1 | NIH | 5/27/2024 | $694,403 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI180334 | PKA-Dependent Autophagy Control in Aspergillus fumigatus Pathogenesis | 001 | 1 | NIH | 9/11/2024 | $25,111 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01HL171034 | ENsuring ACcess to optimal Therapy in CF: ENACT study | 000 | 1 | NIH | 7/17/2024 | $642,460 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01AI179593 | Calcineurin Control over Aspergillus Fumigatus Antifungal Response Mechanisms | 001 | 1 | NIH | 7/2/2024 | $0 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01AI179593 | Calcineurin Control over Aspergillus Fumigatus Antifungal Response Mechanisms | 000 | 1 | NIH | 6/14/2024 | $521,377 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | F30HL165803 | Altered miRNA Expression Drives Proliferation of Lymphatic Malformation by Activating Pro-Growth Signaling Cascades | 000 | 2 | NIH | 8/21/2024 | $39,354 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R21AI173759 | DNA-PKcs Regulation of LAT-Mediated Early TCR Signaling in CD4+ and CD8+ T Cells | 000 | 2 | NIH | 7/3/2024 | $192,500 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01AI170385 | Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial | 000 | 3 | NIH | 8/2/2024 | $1,383,097 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R01AI159684 | Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients | 000 | 5 | NIH | 8/23/2024 | $1 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | K23HL174407 | Multifactorial Asthma Determinants in Underresourced Pediatric Populations | 000 | 1 | NIH | 9/17/2024 | $164,453 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | R35GM142744 | The Role of the Mitochondrion in the Metabolic Stress Response to Burn Trauma | 000 | 4 | NIH | 7/10/2024 | $385,000 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | P20GM109096 | Center for Childhood Obesity Prevention | 001 | 9 | NIH | 9/17/2024 | $2,296,429 |
| | 2024 | 2024 | ARKANSAS CHILDREN'S RESEARCH INSTITUTE | 13 CHILDREN'S WAY | LITTLE ROCK | AR | 72202-3500 | PULASKI | USA | P20GM121293 | Center for Translational Pediatric Research | 000 | 8 | NIH | 8/16/2024 | $2,303,000 |
|
